Recent RCTs (2019–2026) show limited evidence that CBD improves outcomes when added to CBT or exposure therapy for anxiety. While single‑dose lab studies sometimes show acute anxiolytic effects, long‑term, disorder‑level trials are lacking—UK therapists should adopt a cautious, evidence‑informed approach and document shared decisions with patients.

Now that Veoza is available on the NHS for women who cannot take HRT, interest in non‑hormonal options — including low‑dose CBD and hemp‑derived cannabinoids — is rising. This article summarises the current evidence, practical microdosing approaches, safety considerations and how to discuss options with your GP.

Following the FSA's 24 February 2026 update, UK employers must refresh CBD policies to address THC contamination, microdosing and drug‑testing challenges. This article summarises testing methods and costs, data‑protection obligations, the need for Certificates of Analysis (COAs), and pragmatic policy changes HR teams should adopt now.